Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Cellectis has announced its intention to conduct an at-the-market offering (ATM) of up to $60 million in American Depositary Shares (ADS) as of January 4, 2023. This program is set to run until July 6, 2025, unless terminated earlier. The funds raised will primarily support the clinical development of its gene therapies, including UCART 123 and others. The potential dilution for existing shareholders is estimated at approximately 23.04%. Jefferies LLC will act as the sales agent, with shares issued without preferential rights for existing shareholders.
Cellectis (Nasdaq: CLLS) has entered into a collaboration with Primera Therapeutics, facilitated by Mayflower Bioventures. The partnership aims to develop gene editing therapies targeting mitochondrial diseases, which currently lack effective treatments. Primera will leverage its innovations from the Mayo Clinic to address mutations in mitochondrial DNA. Cellectis will acquire a 19% stake in Primera and may earn up to $750 million in milestone payments as well as royalties. This collaboration emphasizes Cellectis’ commitment to addressing unmet medical needs through gene editing.
Cellectis has secured a €40 million credit facility from the European Investment Bank to advance its UCART product pipeline. The facility is structured in three tranches: €20 million for Tranche A, €15 million for Tranche B, and €5 million for Tranche C, each with specific conditions for disbursement. This financing aims to support the development of allogeneic CAR T-cell therapies targeting severe unmet medical needs. The facility is designed to be minimally dilutive for shareholders, carrying a decreasing fixed interest rate, capitalized annually.
Cellectis announced a significant milestone as the first patient was dosed in the U.S. with its UCART22 product candidate, completing the 28-day Dose Limiting Toxicity (DLT) observation period without complications. This achievement underscores Cellectis' in-house manufacturing capabilities, which enhance efficiency in clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company aims to provide timely treatment, controlling the entire process from research and development to clinical manufacturing.
Cellectis announced its total number of shares as of November 30, 2022, standing at 45,579,410, with total voting rights totaling 51,646,286.
Cellectis, listed on both Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS), focuses on gene-editing therapies targeting cancers and blood disorders. Its proprietary technologies include TALEN® and PulseAgile.
The company aims to address unmet medical needs through innovative cell and gene therapies, notably for acute myeloid leukemia and multiple myeloma.
Cellectis S.A. (CLLS) announced updated clinical data from its BALLI-01 and AMELI-01 studies at the ASH 2022 meeting. In the BALLI-01 trial, UCART22 showed anti-tumor activity in 60% of patients at dose level 3 (DL3) after FCA lymphodepletion, with one patient maintaining a durable MRD-negative complete response for over 12 months. Meanwhile, AMELI-01 demonstrated a 25% meaningful response rate at dose level 2 (DL2), including a patient achieving sustained MRD-negative status. The company is now enrolling patients in both studies with in-house manufactured product candidates.
Cellectis, a clinical-stage biotechnology company focused on gene editing, will host a live webcast on December 13, 2022, at 7:30 AM ET. The event will review clinical data from the AMELI-01 study evaluating UCART123 and include a company update. Presentations by the management team will precede a Q&A session. Interested participants can register for the webcast on Cellectis’ website. The company, listed on NASDAQ (CLLS) and Euronext Growth (ALCLS), emphasizes its commitment to developing life-saving therapies using its innovative gene-editing platform.
Cellectis, a clinical-stage biotechnology company, announced the presentation of preclinical data on TALEN®-edited smart CAR T-cells at the SITC 37th Annual Meeting. The data, focusing on targeting solid tumors, includes two key presentations about MUC-1 CAR T-cells and T-cell engineering strategies that improve anti-tumor efficacy while minimizing toxicity. The innovative approaches address challenges faced by CAR T-cell therapies in solid tumors, particularly triple-negative breast cancer. The presentations are available on Cellectis' website following the event.
Cellectis (ticker: CLLS), a clinical-stage biotechnology company, has published a manuscript in Frontiers Bioengineering and Biotechnology showcasing the effectiveness of a multiplex gene editing approach using TALEN® and TALE base editing technologies. This combination enables efficient double gene knock-outs of TRAC and CD52, essential for allogeneic CAR T-cell therapies, with minimal by-products. The study achieved up to 80% and 75% phenotypic knock-outs respectively, paving the way for safer and more controllable gene editing applications in therapeutic settings.
Cellectis reported as of October 31, 2022, a total of 45,567,810 shares in its capital and 51,634,701 voting rights. This biotechnology company specializes in gene-editing and focuses on developing CAR-T immunotherapies for various cancers. Cellectis employs its proprietary TALEN® technology and PulseAgile system to advance treatments for acute myeloid leukemia and other serious conditions. The company continues to expand its portfolio while maintaining a commitment to address unmet medical needs.
